Gradual withdrawal of long-term anticholinergic antiparkinson medication in chinese patients with chronic schizophrenia

Journal of Clinical Psychopharmacology

Volumn 19, Issue 2, 1999, Pages 141-148

  Ungvari, Gabor S ^a,d   Chiu, Helen F K ^a   Lam, Linda C W ^a   Pang, Alfred H T ^a   Chung, Dicky W S ^a   Li, Siu Wah ^b   Chiu, Siu Ning ^c   Lum, Francis C K ^b   Leung, Tony ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CASTLE PEAK HOSPITAL   (Hong Kong)

^c KWAI CHUNG HOSPITAL   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CHLORPROMAZINE; DIAZEPAM; FLUPHENAZINE; HALOPERIDOL; THIORIDAZINE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL;

ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTICLE; CHINESE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; ORAL DRUG ADMINISTRATION; POLYPHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; CHINA; CHRONIC DISEASE; HUMANS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS;

EID: 0032946164     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199904000-00009     Document Type: Article

References (65)

1. McEvoy JP. The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs. J Clin Psychopharmacol 1983;3:288-301.
2. Lake CR, Casey DE, McEvoy JP, Boyer WF, Simpson G. The "pros" and "cons" of anticholinergic prophylaxis. Psychopharmacol Bull 1986;22:981-4.
3. Barnes TRE. Comment on the WHO consensus statement. Br J Psychiatry 1990;156:413-4.
4. Lavin MR, Rifkin A. Prophylactic antiparkinson drug use; II. Withdrawal after long-term maintenance therapy. J Clin Pharmacol 1991;31:769-77.
5. Lavin MR, Rifkin A. Neuroleptic-induced Parkinsonism. In: Kane JM, Lieberman JA, eds. Adverse effects of psychotropic drugs. New York: Guilford Press, 1992:175-88.
6. Baker LA, Cheng LY, Amara IB. The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry 1983; 143:584-90.
7. McEvoy JP, Freter S. The dose-response relationship for memory impairment by anticholinergic drugs. Compr Psychiatry 1989; 30:135-8.
8. Land W, Pinsky D, Salzman C. Abuse and misuse of anticholinergic medications. Hosp Community Psychiatry 1991;42:580-1.
9. Longo VG. Behavioral and electroencephalographic effects of atropine and related compounds. Pharmacol Rev 1969;18:965-96.
10. Gautier J, Jus A, Villeneuve A, Jus K, Pires P. Influence of the antiparkinsonian drugs on the plasma level of neuroleptics. Biol Psychiatry 1977;12:389-99.
11. Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. Arch Gen Psychiatry 1989;46:745-53.
12. Simpson GM, Cooper TB, Bark N, Sud I, Lee H. Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Arch Gen Psychiatry 1980;37:205-8.
13. Goff DC, Arana GW, Greenblatt DJ, Dupont R, Ornsteen M, Harmatz JS, Shader RI. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol 1991;11: 106-12.
14. Perris C, Dimitrijevic P, Jacobsson L, Paulsson P, Rapp W, Foberg H. Tardive dyskinesia in psychiatric patients treated with neuroleptics. Br J Psychiatry 1979;135:509-14.
15. Gardos G, Cole JO, Rapkin RM, LaBrie RA, Baquelod E, Moore P, Sovner R, Doyle J. Anticholinergic challenge and neuroleptic withdrawal. Arch Gen Psychiatry 1984;41:1030-5.
16. Greil W, Haag H, Rossnagl G, Ruther E. Effect of anticholinergics on tardive dyskinesia. Br J Psychiatry 1984;145:304-10.
17. Gerlach J, Rasmussen PT, Hansen L, Kristjansen P. Antiparkinson agents and long-term neuroleptic treatment. Acta Psychiatr Scand 1977;55:251-60.
18. Rifkin A, Quitkin F, Kane J, Struve F, Klein DF. Are prophylactic antiparkinson drugs necessary? Arch Gen Psychiatry 1978; 35:483-9.
19. Vagen R, Gotestam KG. An experimental evaluation of the euphoric properties of antiparkinson drugs on psychotic patients. Acta Psychiatr Scand 1986;74:519-23.
20. Double DB, Warren GC, Evans M, Rowlands MP. Efficacy of main tenance use of anticholinergic agents. Acta Psychiatr Scand 1993; 88:381-4.
21. McInnis M, Petursson H. Withdrawal of trihexyphenidyl. Acta Psychiatr Scand 1985;71:297-303.
22. Manos N, Gkiouzepas J, Logothetis J. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy. Am J Psychiatry 1981;138:184-8.
23. Jellinek T, Gardos G, Cole JO. Adverse effects of antiparkinson drug withdrawal. Am J Psychiatry 1981;138:1567-71.
24. Manos N, Gkiouzepas J. Discontinuing antiparkinson medication in chronic schizophrenics: at what cost to the patient? Acta Psychiatr Scand 1981;63:28-32.
25. Double DB. Unblinding in trials of the withdrawal of anticholinergic agents in patients maintained on neuroleptics. J Nerv Ment Dis 1995;183:599-602.
26. Manos N, Gkiouzepas J, Tzotzoras T, Tzanegtoglou A. Gradual withdrawal of antiparkinson medication in chronic schizophrenic patients: any better than the abrupt? J Nerv Ment Dis 1981; 169:659-61.
27. Caradoc-Davies G, Menkes DB, Clarkson HO, Mullen PE. A study of the need for anticholinergic medication in patients treated with long-term antipsychotics. Aust NZ J Psychiatry 1986;20:225-32.
28. Lin K-M, Finder E. Neuroleptic dosage for Asians. Am J Psychiatry 1983;140:490-1.
29. Sramek JJ, Sayler MA, Simpson GM. Neuroleptic dosage for Asians: a failure to replicate. Am J Psychiatry 1986;143:535-6.
30. Lin K-M, Anderson D, Poland RE. Ethnicity and psychopharmacology. Psychiatr Clin North Am 1995;18:635-47.
31. Binder RL, Levy R. Extrapyramidal reactions in Asians. Am J Psychiatry 1981;138:1243-4.
32. Chiu H, Shum P, Lau J, Lam L, Lee S. Prevalence of tardive dyskinesia, tardive dystonia and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Am J Psychiatry 1992; 149:1081-5.
33. Ungvari GS, Pang AHT, Chiu HFK, Wong CK, Lum FCK. Psychotropic drug prescription in rehabilitation. Soc Psychiatry Psychiatr Epidemiol 1996;31:288-91.
34. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45[suppl 212]:11-9.
35. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72.
36. Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 1988;24:112-7.
37. Williams JBW. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988;45:742-7.
38. Guy W. ECDEU Assessment for psychopharmacology. Washington, DC: HEW Public Health Service, 1976:534-7.
39. Munitz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988;39:1172-7.
40. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
41. Burke RE, Fahn S. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 1985;18:35-40.
42. Rifkin A, Quitkin F, Klein DF. Akinesia. Arch Gen Psychiatry 1975:672-4.
43. Honigfeld G, Gillis RD, Klett CJ. NOSIE-30: a treatment-sensitive ward behavior scale. Psychol Rep 1966;19:180-2.
44. Mindham RHS, Gaind R, Austee BH, Rimmer L. Comparison of amantadine, orphenadrine and placebo in the control of phenothiazine-induced parkinsonism. Psychol Med 1972;2:406-13.
45. Loga S, Curry S, Lader M. Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentration and effects in man. Br J Clin Pharmacol 1975;2:197-208.
46. Carter G. The abrupt withdrawal of antiparkinsonian drugs in mentally handicapped patients. Br J Psychiatry 1983;14:166-8.
47. McEvoy JP, McCue M, Freter S. Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia. Clin Ther 1987;9: 429-33.
48. Cheng LY, Baker L, Amara IB. Neuroleptics, antiparkinsonian medication and schizophrenia [letter]. Am J Psychiatry 1981;138: 1389-90.
49. Lin KM, Poland RE, Nuccio I, Matsuda K, Hathuc N, Su TP, Fu P. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry 1989;146:1307-11.
50. Matsuda KT, Cho MC, Lin K-M, Smith MW, Young AS, Adams JA. Clozapine dosage, serum levels, efficacy and side effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 1996;32:253-7.
51. Chang WH, Chen TY, Lee CF, Hu WH, Yeh EK. Low plasma reduced haloperidol/haloperidol ratio in Chinese patients. Biol Psychiatry 1987;22:1406-8.
52. Jeste DV, Lindamer LA, Evans J, Lacro JP. Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol Bull 1996;32:243-51.
53. Lin K-M, Poland RE, Wan YJ, Smith MW, Lesser IM. The evolving science of pharmacogenetics: clinical and ethnic perspectives. Psychopharmacol Bull 1996;32:205-17.
54. Smith M, Lin KM, Mendoza R. "Non-biological" factors affecting psychopharmacotherapy: cultural considerations. In: Lin KM, Poland RE, Nakasaki G, eds. Psychopharmacology and psychobiology of ethnicity. Washington, DC: American Psychiatric Press, 1993:37-58.
55. Segal SP, Bola JR, Watson MA. Race, quality of care and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr Serv 1996;47:282-6.
56. Ko GN, Zhang LD, Yan WW, Zhang MD, Buchner D, Xia ZY, Wyatt RJ, Jeste DV. The Shanghai 800: prevalence of tardive dyskinesia in a Chinese psychiatric hospital. Am J Psychiatry 1989;146:387-9.
57. Chiu HFK, Shum PS, Lam CW. Psychotropic drug prescribing to chronic schizophrenics in Hong Kong. Int J Soc Psychiatry 1991; 37:187-91.
58. Wada Y, Koshino Y, Yamaguchi N. Biperiden withdrawal in schizophrenic inpatients receiving long-term antipsychotic medication. Clin Neuropharmacol 1987;10:370-5.
59. Jin Z. Effect of an open-door policy combined with a structured activity programme on the residual symptoms of schizophrenic in-patients. Br J Psychiatry 1994;165[suppl 24]:52-7.
60. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79-91.
61. Ungvari GS, Chow LY, Chiu HFK, Ng FS, Leung T. Modifying psychotropic drug prescription patterns: a follow-up survey. Psychiatr Clin Neurosci 1997;51:312-8.
62. Stratas NE, Phillips RD, Walker PA, Sandifer MD. A study of drug-induced parkinsonism. Dis Nerv Syst 1963;24:180.
63. Klett CJ, Caffey E. Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics. Arch Gen Psychiatry 1972; 26:374-9.
64. World Health Organization. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement [review]. Br J Psychiatry 1990;156:412.
65. Kane JM, Evans DL, Fiester SJ, Mirin SM, Pincus HA, Schatzberg AF, Cole JO, Popper CW, Psychopharmacological screening criteria. J Clin Psychiatry 1992;53:184-96.